<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<database>
    <TRIAL>
        <attritionBiasJudgement>The rate of leaving the study early was only 5% and data on reasons for leaving early were provided. All data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Bai2005</authorYearLetter>
        <blindingMethod>SINGLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>40</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </dobj>
        <mainAuthor>Bai</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>Insufficient data to judge on baseline imbalance or industry sponsoring.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>40</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, Chen TT, Chen JY, Lin CY, Chou P</allAuthors>
            <date>2005</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S473</pages>
            <title>Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study</title>
            <type>Journal article</type>
            <volume>15</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, Chen TT, Chen JY, Lin CY, Chou P</allAuthors>
            <date>2005</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S473</pages>
            <title>Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study</title>
            <type>Journal article</type>
            <volume>15</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, Chen TT, Chen JY, Lin CY, Chou P</references>
        <references>Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study</references>
        <references>Journal of the European College of Neuropsychopharmacology</references>
        <references>2005</references>
        <references>15</references>
        <references>Suppl 3</references>
        <references>S473</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The study is only available as an abstract. Data on BPRS and EPS scales were not available.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Bai-2005</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>NOTAVAILABLE</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2005</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of participants leaving the study early was below 10% and data on reasons for leaving early were available. The data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Hwang2003</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-10.0</Control_Mean>
            <Control_SD>14.5</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-11.1</Intervention_Mean>
            <Intervention_SD>13.9</Intervention_SD>
            <Outcome>General functioning: 1b. General - average score at endpoint (SOFAS total score, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </dobj>
        <mainAuthor>Hwang</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of amisulpride.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by the original studies)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>rigor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>7</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>23</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-28.4</Control_Mean>
            <Control_SD>18.8</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-24.1</Intervention_Mean>
            <Intervention_SD>17.2</Intervention_SD>
            <Outcome>Mental state: 1c. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-17.7</Control_Mean>
            <Control_SD>11.5</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-14.9</Intervention_Mean>
            <Intervention_SD>10.7</Intervention_SD>
            <Outcome>Mental state: 1f. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-8.3</Control_Mean>
            <Control_SD>6.1</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-6.8</Intervention_Mean>
            <Intervention_SD>6.0</Intervention_SD>
            <Outcome>Mental state: 2a. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-6.4</Control_Mean>
            <Control_SD>4.8</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-5.6</Intervention_Mean>
            <Intervention_SD>4.5</Intervention_SD>
            <Outcome>Mental state: 3a. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-10.0</Control_Mean>
            <Control_SD>14.5</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>22</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>25</Control_Total>
            <Intervention_Mean>-11.1</Intervention_Mean>
            <Intervention_SD>13.9</Intervention_SD>
            <Outcome>General functioning: 1b. General - average score at endpoint (SOFAS total score, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, Chen Y-S</allAuthors>
            <date>2003</date>
            <issue>1</issue>
            <journalName>Journal of the Formosan Medical Association</journalName>
            <originalTitle></originalTitle>
            <pages>30-6</pages>
            <title>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan</title>
            <type>Journal article</type>
            <volume>102</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, Chen Y-S</allAuthors>
            <date>2003</date>
            <issue>1</issue>
            <journalName>Journal of the Formosan Medical Association</journalName>
            <originalTitle></originalTitle>
            <pages>30-6</pages>
            <title>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan</title>
            <type>Journal article</type>
            <volume>102</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, Chen Y-S</references>
        <references>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan</references>
        <references>Journal of the Formosan Medical Association</references>
        <references>2003</references>
        <references>102</references>
        <references>1</references>
        <references>30-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Taiwan</references>
        <references></references>
        <reportingBiasJudgement>Data on the extrapyramidal symptom scale have not been presented. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Hwang-2003</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>NOTAVAILABLE</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2003</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of leaving the study early was high (57.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if they had remained in the study. This assumption can often be wrong and poses a problem given the high attrition.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Lecrubier2006</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-4.35</Control_Mean>
            <Control_SD>5.21</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>-4.3</Intervention_Mean>
            <Intervention_SD>4.9</Intervention_SD>
            <Outcome>Mental state: 3c. Negative symptoms - average score at endpoint (SANS total score, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>31</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </dobj>
        <mainAuthor>Lecrubier</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was industry sponsored by the manufacturers of olanzapine and one of the authors is an employee of that company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>41</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>80</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>34</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 2. Death</Outcome>
            <Subgroup>suicide attempt</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>28</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>dyskinesia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>18</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>30</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>extrapyramidal symptoms</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>parkinsonism</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>7</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>46</Control_Total>
            <Outcome>Adverse effects: 7. Prolactin associated side effects</Outcome>
            <Subgroup>amenorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>20</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>46</Control_Total>
            <Outcome>Adverse effects: 7. Prolactin associated side effects</Outcome>
            <Subgroup>galactorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>50</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>94</Control_Total>
            <Outcome>Adverse effects: 7. Prolactin associated side effects</Outcome>
            <Subgroup>sexual dysfunction</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>6</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control_Events>31</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-19.45</Control_Mean>
            <Control_SD>24.77</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>-13.7</Intervention_Mean>
            <Intervention_SD>25.4</Intervention_SD>
            <Outcome>Mental state: 1b. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-9.45</Control_Mean>
            <Control_SD>14.33</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>-6.0</Intervention_Mean>
            <Intervention_SD>15.0</Intervention_SD>
            <Outcome>Mental state: 1d. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-1.0</Control_Mean>
            <Control_SD>6.6</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>1.2</Intervention_Mean>
            <Intervention_SD>8.3</Intervention_SD>
            <Outcome>Mental state: 2b. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-7.6</Control_Mean>
            <Control_SD>8.03</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>-7.0</Intervention_Mean>
            <Intervention_SD>7.8</Intervention_SD>
            <Outcome>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-4.35</Control_Mean>
            <Control_SD>5.21</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>70</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>140</Control_Total>
            <Intervention_Mean>-4.3</Intervention_Mean>
            <Intervention_SD>4.9</Intervention_SD>
            <Outcome>Mental state: 3c. Negative symptoms - average score at endpoint (SANS total score, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S</allAuthors>
            <date>2006</date>
            <issue></issue>
            <journalName>Acta Psychiatrica Scandinavica</journalName>
            <originalTitle></originalTitle>
            <pages>319-27</pages>
            <title>The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial</title>
            <type>Journal article</type>
            <volume>114</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S</allAuthors>
            <date>2006</date>
            <issue></issue>
            <journalName>Acta Psychiatrica Scandinavica</journalName>
            <originalTitle></originalTitle>
            <pages>319-27</pages>
            <title>The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial</title>
            <type>Journal article</type>
            <volume>114</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S</references>
        <references>The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial</references>
        <references>Acta Psychiatrica Scandinavica</references>
        <references>2006</references>
        <references>114</references>
        <references></references>
        <references>319-27</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Lecrubier-2006</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2006</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of leaving the study early was 35.8%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong. It is unclear whether this led to bias .</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Mortimer2005</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-0.1</Control_Mean>
            <Control_SD>0.4</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>185</Control_Total>
            <Intervention_Mean>-0.1</Intervention_Mean>
            <Intervention_SD>0.4</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, identical capsules ("to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided"). Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>39</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>66</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>weight gain of 7% or more of total body weight</Subgroup>
        </dobj>
        <mainAuthor>Mortimer</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of amisulpride.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>81</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>76</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by original studies)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>72</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>63</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>16</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>20</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>25</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 2. Death</Outcome>
            <Subgroup>natural causes</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 2. Death</Outcome>
            <Subgroup>suicide</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>5</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>dystonia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>parkinsonism</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>26</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>17</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 7. Prolactin associated side effects</Outcome>
            <Subgroup>sexual dysfunction</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>39</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>189</Intervention_Total>
            <Control_Events>66</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>188</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>weight gain of 7% or more of total body weight</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-27.3</Control_Mean>
            <Control_SD>25.7</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>186</Control_Total>
            <Intervention_Mean>-26.8</Intervention_Mean>
            <Intervention_SD>26.6</Intervention_SD>
            <Outcome>Mental state: 1b. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-18.2</Control_Mean>
            <Control_SD>15.3</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>186</Control_Total>
            <Intervention_Mean>-18.3</Intervention_Mean>
            <Intervention_SD>16.2</Intervention_SD>
            <Outcome>Mental state: 1d. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-11.2</Control_Mean>
            <Control_SD>8.3</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>186</Control_Total>
            <Intervention_Mean>-11.2</Intervention_Mean>
            <Intervention_SD>8.5</Intervention_SD>
            <Outcome>Mental state: 2b. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-3.0</Control_Mean>
            <Control_SD>6.8</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>186</Control_Total>
            <Intervention_Mean>-2.7</Intervention_Mean>
            <Intervention_SD>6.8</Intervention_SD>
            <Outcome>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-0.5</Control_Mean>
            <Control_SD>3.6</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>181</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>175</Control_Total>
            <Intervention_Mean>-0.9</Intervention_Mean>
            <Intervention_SD>3.4</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>abnormal involuntary movement: AIMS (high=poor)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-0.1</Control_Mean>
            <Control_SD>0.4</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>186</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>185</Control_Total>
            <Intervention_Mean>-0.1</Intervention_Mean>
            <Intervention_SD>0.4</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, identical capsules ("to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided"). Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Möller HJ, Riedel M, Eich FX</allAuthors>
            <date>2005</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S511</pages>
            <title>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</title>
            <type>Journal article</type>
            <volume>15</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Möller HJ, Riedel M, Eich FX</allAuthors>
            <date>2005</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S511</pages>
            <title>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</title>
            <type>Journal article</type>
            <volume>15</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Möller HJ, Riedel M, Eich FX</references>
        <references>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</references>
        <references>Journal of the European College of Neuropsychopharmacology</references>
        <references>2005</references>
        <references>15</references>
        <references>Suppl 3</references>
        <references>S511</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Only treatment emergent adverse events occurring in 5% of the participants are presented, therefore important side effects may have been missed by this procedure.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Mortimer-2004</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>The computer generated randomisation list was prepared and kept outside the study centre. The participant numbers were assigned in strict chronological order in each centre.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, computer-generated randomisation.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2005</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>Numbers of participants leaving the study early were only reported for the category 'due to adverse effects'. The statistical method used to account for incomplete data was not described.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>M_x00f6_ller2004</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </dobj>
        <mainAuthor>M_x00f6_ller</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of amisulpride. Whether there was baseline imbalance could not be judged due to insufficient data.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>24</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>12</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="otherReferenceObject">
            <allAuthors>Singh V</allAuthors>
            <date>2001</date>
            <issue></issue>
            <originalTitle></originalTitle>
            <pages></pages>
            <source>National Research Register</source>
            <title>A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg/day verses olanzapine 5 to 20 mg/day in patients with schizophrenic disorders</title>
            <type>Other reference</type>
            <volume>1</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Mortimer A, Martin S, Loo H, Peuskens J, SOLIANOL Sudy Group</allAuthors>
            <date>2004</date>
            <issue>2</issue>
            <journalName>International Clinical Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>63-9</pages>
            <title>A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia</title>
            <type>Journal article</type>
            <volume>19</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="otherReferenceObject">
            <allAuthors>Mortimer A</allAuthors>
            <date>2003</date>
            <issue></issue>
            <originalTitle></originalTitle>
            <pages></pages>
            <source>National Research Register</source>
            <title>The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST)</title>
            <type>Other reference</type>
            <volume>1</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="otherReferenceObject">
            <allAuthors>Singh V</allAuthors>
            <date>2001</date>
            <issue></issue>
            <originalTitle></originalTitle>
            <pages></pages>
            <source>National Research Register</source>
            <title>A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg/day verses olanzapine 5 to 20 mg/day in patients with schizophrenic disorders</title>
            <type>Other reference</type>
            <volume>1</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Mortimer A, Martin S, Loo H, Peuskens J, SOLIANOL Sudy Group</references>
        <references>A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia</references>
        <references>International Clinical Psychopharmacology</references>
        <references>2004</references>
        <references>19</references>
        <references>2</references>
        <references>63-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>England</references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Mortimer A</references>
        <references>The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST)</references>
        <references>National Research Register</references>
        <references>2003</references>
        <references>1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Singh V</references>
        <references>A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg/day verses olanzapine 5 to 20 mg/day in patients with schizophrenic disorders</references>
        <references>National Research Register</references>
        <references>2001</references>
        <references>1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-M_x00f6_ller-2005</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>NOTAVAILABLE</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2004</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of leaving the study early was about 25%, the analysis was based on the 'least squares mean change' (last-observation-carried-forward). It is unclear whether the degree of attrition and the method used to account for it led to bias.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Olie2006</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>21</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Adverse effects: 4. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </dobj>
        <mainAuthor>Olie</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturers of ziprasidone.The dose of ziprasidone could be increased to the maximum daily dose, whereas amisulpride could only be increased up to 200 mg which might lead to a bias in terms of efficacy and side effects occurrence.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>9</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Adverse effects: 4. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Adverse effects: 4. Extrapyramidal effects</Outcome>
            <Subgroup>parkinsonism</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus ZIPRASIDONE - all data short term</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>63</Intervention_Total>
            <Control_Events>21</Control_Events>
            <Control> ziprasidone - all data short term</Control>
            <group2NameProse> ziprasidone - all data short term</group2NameProse>
            <Control_Total>60</Control_Total>
            <Outcome>Adverse effects: 4. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Olie JP, Spina E, Benattia I</allAuthors>
            <date>2002</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S313</pages>
            <title>Ziprasidone vs amisulpride for negative symptoms of schizophrenia</title>
            <type>Journal article</type>
            <volume>12</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Olie J-P, Spina E, Murray S, Yang R</allAuthors>
            <date>2006</date>
            <issue>3</issue>
            <journalName>International Clinical Psychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>143-51</pages>
            <title>Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study</title>
            <type>Journal article</type>
            <volume>21</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Olie JP, Spina E, Benattia I</allAuthors>
            <date>2002</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S313</pages>
            <title>Ziprasidone vs amisulpride for negative symptoms of schizophrenia</title>
            <type>Journal article</type>
            <volume>12</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Olie J-P, Spina E, Murray S, Yang R</references>
        <references>Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study</references>
        <references>International Clinical Psychopharmacology</references>
        <references>2006</references>
        <references>21</references>
        <references>3</references>
        <references>143-51</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>United Kingdom</references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Olie JP, Spina E, Benattia I</references>
        <references>Ziprasidone vs amisulpride for negative symptoms of schizophrenia</references>
        <references>Journal of the European College of Neuropsychopharmacology</references>
        <references>2002</references>
        <references>12</references>
        <references>Suppl 3</references>
        <references>S313</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Predefined laboratory data and data on the Global Assessment of Functioning Scale have not been presented. Treatment emergent adverse events had to occur with an incidence of 5% for reporting, therefore important side effects may have been missed by this procedure.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Olie-2006</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>OUTPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2006</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of leaving the study early was 30.3%. Statistical analysis was based on an intent to treat basis. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Peuskens1999</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>0.35</Control_Mean>
            <Control_SD>1.7</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>0.29</Intervention_Mean>
            <Intervention_SD>1.7</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 7a. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </dobj>
        <mainAuthor>Peuskens</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of amisulpride.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>48</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by the original studies)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>37</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>32</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>15</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>10</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>13</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>12</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>38</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>33</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>extrapyramidal symptoms</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>11</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>hyperkinesia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>16</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>13</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>parkinsonism</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>8</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>rigor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>8</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>35</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>26</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>47</Control_Total>
            <Outcome>Adverse effects: 6. Prolactin associated side effects</Outcome>
            <Subgroup>galactorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>71</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>66</Control_Total>
            <Outcome>Adverse effects: 6. Prolactin associated side effects</Outcome>
            <Subgroup>sexual dysfunction</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Outcome>Adverse effects: 7a. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-15.2</Control_Mean>
            <Control_SD>13.9</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>-17.7</Intervention_Mean>
            <Intervention_SD>14.9</Intervention_SD>
            <Outcome>Mental state: 1f. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-8.6</Control_Mean>
            <Control_SD>7.4</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>-9.6</Intervention_Mean>
            <Intervention_SD>8.5</Intervention_SD>
            <Outcome>Mental state: 2a. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-6.7</Control_Mean>
            <Control_SD>5.3</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>-7.2</Intervention_Mean>
            <Intervention_SD>5.4</Intervention_SD>
            <Outcome>Mental state: 2b. Positive symptoms - average score at endpoint - short term (BPRS positive subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-5.3</Control_Mean>
            <Control_SD>6.6</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>-6.9</Intervention_Mean>
            <Intervention_SD>7.5</Intervention_SD>
            <Outcome>Mental state: 3a. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>1.7</Control_Mean>
            <Control_SD>3.88</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>2.0</Intervention_Mean>
            <Intervention_SD>3.88</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>abnormal involuntary movement: AIMS (high=poor)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>0.35</Control_Mean>
            <Control_SD>1.7</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>115</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>113</Control_Total>
            <Intervention_Mean>0.29</Intervention_Mean>
            <Intervention_SD>1.7</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W</allAuthors>
            <date>1999</date>
            <issue></issue>
            <journalName>Psychiatry Research</journalName>
            <originalTitle></originalTitle>
            <pages>107-17</pages>
            <title>Amisulpride vs. risperidone in the treatment of acute exacerations of schizophrenia</title>
            <type>Journal article</type>
            <volume>88</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W</allAuthors>
            <date>1999</date>
            <issue></issue>
            <journalName>Psychiatry Research</journalName>
            <originalTitle></originalTitle>
            <pages>107-17</pages>
            <title>Amisulpride vs. risperidone in the treatment of acute exacerations of schizophrenia</title>
            <type>Journal article</type>
            <volume>88</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W</references>
        <references>Amisulpride vs. risperidone in the treatment of acute exacerations of schizophrenia</references>
        <references>Psychiatry Research</references>
        <references>1999</references>
        <references>88</references>
        <references></references>
        <references>107-17</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Data on general functioning (a secondary outcome) were not available. Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Peuskens-1999</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>1999</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of participants leaving the study early was considerable (40%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Sechter2002</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-0.07</Control_Mean>
            <Control_SD>0.41</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Intervention_Mean>-0.1</Intervention_Mean>
            <Intervention_SD>0.45</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>18</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>32</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 7a. Metabolic - weight - gain</Outcome>
            <Subgroup>weight gain of 7% or more of total body weight</Subgroup>
        </dobj>
        <mainAuthor>Sechter</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of amisulpride.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>59</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>78</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by the original studies)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>54</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>69</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>21</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>20</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>11</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>18</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 2. Death</Outcome>
            <Subgroup>natural causes</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 2. Death</Outcome>
            <Subgroup>suicide</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>35</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>48</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>akathisia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>29</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>22</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>hyperkinesia</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>18</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>27</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>parkinsonism</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>4</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>tremor</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>36</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>47</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 5a. Extrapyramidal effects</Outcome>
            <Subgroup>use of antiparkinson medication</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>69</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>71</Control_Total>
            <Outcome>Adverse effects: 6. Prolactin associated side effects</Outcome>
            <Subgroup>amenorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>69</Intervention_Total>
            <Control_Events>1</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>71</Control_Total>
            <Outcome>Adverse effects: 6. Prolactin associated side effects</Outcome>
            <Subgroup>galactorrhea</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>0</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>83</Intervention_Total>
            <Control_Events>6</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>87</Control_Total>
            <Outcome>Adverse effects: 6. Prolactin associated side effects</Outcome>
            <Subgroup>sexual dysfunction</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Intervention_Events>18</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control_Events>32</Control_Events>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Outcome>Adverse effects: 7a. Metabolic - weight - gain</Outcome>
            <Subgroup>weight gain of 7% or more of total body weight</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-31.4</Control_Mean>
            <Control_SD>21.0</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>121</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>123</Control_Total>
            <Intervention_Mean>-32.2</Intervention_Mean>
            <Intervention_SD>23.9</Intervention_SD>
            <Outcome>Mental state: 1c. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-19.6</Control_Mean>
            <Control_SD>12.6</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>121</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>123</Control_Total>
            <Intervention_Mean>-19.8</Intervention_Mean>
            <Intervention_SD>15.0</Intervention_SD>
            <Outcome>Mental state: 1f. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-12.1</Control_Mean>
            <Control_SD>6.9</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>121</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>123</Control_Total>
            <Intervention_Mean>-11.8</Intervention_Mean>
            <Intervention_SD>7.5</Intervention_SD>
            <Outcome>Mental state: 2a. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-3.9</Control_Mean>
            <Control_SD>6.1</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>121</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>123</Control_Total>
            <Intervention_Mean>-5.1</Intervention_Mean>
            <Intervention_SD>5.1</Intervention_SD>
            <Outcome>Mental state: 3a. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-11.9</Control_Mean>
            <Control_SD>14.3</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>121</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>123</Control_Total>
            <Intervention_Mean>-14.5</Intervention_Mean>
            <Intervention_SD>17.4</Intervention_SD>
            <Outcome>General functioning: 1b. General - average score at endpoint (SOFAS total score, high=poor)</Outcome>
            <Subgroup>medium term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-0.1</Control_Mean>
            <Control_SD>4.1</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Intervention_Mean>-0.16</Intervention_Mean>
            <Intervention_SD>3.17</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>abnormal involuntary movement: AIMS (high=poor)</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus RISPERIDONE</Comparison>
            <Control_Mean>-0.07</Control_Mean>
            <Control_SD>0.41</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>152</Intervention_Total>
            <Control> risperidone</Control>
            <group2NameProse> risperidone</group2NameProse>
            <Control_Total>158</Control_Total>
            <Intervention_Mean>-0.1</Intervention_Mean>
            <Intervention_SD>0.45</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</allAuthors>
            <date>2002</date>
            <issue></issue>
            <journalName>Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>1071-81</pages>
            <title>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study</title>
            <type>Journal article</type>
            <volume>27</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Nicholls CJ, Hale AS, Freemantle N</allAuthors>
            <date>2003</date>
            <issue>2</issue>
            <journalName>Journal of Drug Assessment</journalName>
            <originalTitle></originalTitle>
            <pages>79-89</pages>
            <title>Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia</title>
            <type>Journal article</type>
            <volume>6</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</allAuthors>
            <date>2002</date>
            <issue></issue>
            <journalName>Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>1071-81</pages>
            <title>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study</title>
            <type>Journal article</type>
            <volume>27</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Nicholls CJ, Hale AS, Freemantle N</references>
        <references>Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia</references>
        <references>Journal of Drug Assessment</references>
        <references>2003</references>
        <references>6</references>
        <references>2</references>
        <references>79-89</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</references>
        <references>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study</references>
        <references>Neuropsychopharmacology</references>
        <references>2002</references>
        <references>27</references>
        <references></references>
        <references>1071-81</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Sechter-2002</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2002</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of participants leaving the study early was 16.5% and reasons for leaving the study early were provided. The analysis was based on the last-observation carried forward method with two people being excluded due to no exploitable outcome data. In addition there was a per protocol population which excluded subjects with a major protocol deviation. As two different methods with similar results were applied and as the overall attrition was low we do not think that there was a bias.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Vanelle2006</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-3.56</Control_Mean>
            <Control_SD>3.1</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>39</Control_Total>
            <Intervention_Mean>-3.3</Intervention_Mean>
            <Intervention_SD>3.63</Intervention_SD>
            <Outcome>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </dobj>
        <mainAuthor>Vanelle</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturers of amisulpride. There was a relatively high number of participants (18) with major protocol deviations.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>16</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>16</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by original studies)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>10</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>4</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>0</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>1</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>45</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>40</Control_Total>
            <Outcome>Adverse effects: 8d. Metabolic - weight - gain</Outcome>
            <Subgroup>as "weight gain" reported adverse event</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-17.82</Control_Mean>
            <Control_SD>12.47</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>39</Control_Total>
            <Intervention_Mean>-14.89</Intervention_Mean>
            <Intervention_SD>14.78</Intervention_SD>
            <Outcome>Mental state: 1b. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-11.49</Control_Mean>
            <Control_SD>7.54</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>39</Control_Total>
            <Intervention_Mean>-10.09</Intervention_Mean>
            <Intervention_SD>9.07</Intervention_SD>
            <Outcome>Mental state: 1d. General - average score at endpoint (BPRS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-3.31</Control_Mean>
            <Control_SD>3.15</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>39</Control_Total>
            <Intervention_Mean>-2.32</Intervention_Mean>
            <Intervention_SD>4.14</Intervention_SD>
            <Outcome>Mental state: 2b. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-3.56</Control_Mean>
            <Control_SD>3.1</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>44</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>39</Control_Total>
            <Intervention_Mean>-3.3</Intervention_Mean>
            <Intervention_SD>3.63</Intervention_SD>
            <Outcome>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Vanelle JM, Douki S</allAuthors>
            <date>2004</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S284</pages>
            <title>Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine</title>
            <type>Journal article</type>
            <volume>14</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Vanelle JM, Douki S</allAuthors>
            <date>2006</date>
            <issue></issue>
            <journalName>European Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>523-30</pages>
            <title>A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression</title>
            <type>Journal article</type>
            <volume>21</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Vanelle JM, Douki S</allAuthors>
            <date>2004</date>
            <issue>Suppl 3</issue>
            <journalName>Journal of the European College of Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>S284</pages>
            <title>Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine</title>
            <type>Journal article</type>
            <volume>14</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Vanelle JM, Douki S</references>
        <references>A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression</references>
        <references>European Psychiatry</references>
        <references>2006</references>
        <references>21</references>
        <references></references>
        <references>523-30</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Vanelle JM, Douki S</references>
        <references>Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine</references>
        <references>Journal of the European College of Neuropsychopharmacology</references>
        <references>2004</references>
        <references>14</references>
        <references>Suppl 3</references>
        <references>S284</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Data on extrapyramidal symptoms were not provided.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Vanelle-2006</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, no further details.</selectionBiasRandomSequenceJudgement>
        <setting>INANDOUT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2006</year>
    </TRIAL>
    <TRIAL>
        <attritionBiasJudgement>The rate of participants leaving the study early was high (50%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong and lead to bias in cases of high attrition.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Wagner2005</authorYearLetter>
        <blindingMethod>DOUBLEBLIND</blindingMethod>
        <cobj outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-0.24</Control_Mean>
            <Control_SD>1.71</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>17</Control_Total>
            <Intervention_Mean>0.56</Intervention_Mean>
            <Intervention_SD>6.46</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </cobj>
        <countries></countries>
        <designAddedInfo></designAddedInfo>
        <designProse>Design: parallel</designProse>
        <detectionBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </dobj>
        <mainAuthor>Wagner</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <otherBiasJudgement>The study was sponsored by the manufacturer of olanzapine.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>14</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>20</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Global State: 1b. No clinically important change (as defined by original studies)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>12</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>14</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to any reason</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>3</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>3</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to adverse events</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="dichotomousOutcomeObject" outcomeType="Dichotomous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Intervention_Events>2</Intervention_Events>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>26</Intervention_Total>
            <Control_Events>2</Control_Events>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>26</Control_Total>
            <Outcome>Leaving the study early</Outcome>
            <Subgroup>due to inefficacy</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-33.33</Control_Mean>
            <Control_SD>22.15</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>18</Control_Total>
            <Intervention_Mean>-45.28</Intervention_Mean>
            <Intervention_SD>23.53</Intervention_SD>
            <Outcome>Mental state: 1b. General - average score at endpoint (PANSS total, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-10.61</Control_Mean>
            <Control_SD>5.98</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>18</Control_Total>
            <Intervention_Mean>-12.28</Intervention_Mean>
            <Intervention_SD>4.78</Intervention_SD>
            <Outcome>Mental state: 2b. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-6.83</Control_Mean>
            <Control_SD>6.73</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>18</Control_Total>
            <Intervention_Mean>-9.56</Intervention_Mean>
            <Intervention_SD>6.72</Intervention_SD>
            <Outcome>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-26.06</Control_Mean>
            <Control_SD>24.46</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>17</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>16</Control_Total>
            <Intervention_Mean>-34.68</Intervention_Mean>
            <Intervention_SD>31.21</Intervention_SD>
            <Outcome>Mental state: 3c. Negative symptoms - average score at endpoint (SANS total score, high=poor)</Outcome>
            <Subgroup>short term</Subgroup>
        </OUTCOME>
        <OUTCOME xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="continuousOutcomeObject" outcomeType="Continuous">
            <Comparison>AMISULPRIDE versus OLANZAPINE</Comparison>
            <Control_Mean>-0.24</Control_Mean>
            <Control_SD>1.71</Control_SD>
            <Intervention>treatment</Intervention>
            <group1NameProse></group1NameProse>
            <Intervention_Total>18</Intervention_Total>
            <Control> olanzapine</Control>
            <group2NameProse> olanzapine</group2NameProse>
            <Control_Total>17</Control_Total>
            <Intervention_Mean>0.56</Intervention_Mean>
            <Intervention_SD>6.46</Intervention_SD>
            <Outcome>Adverse effects: 5b. Extrapyramidal effects - scale measured</Outcome>
            <Subgroup>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</Subgroup>
        </OUTCOME>
        <performanceBiasJudgement>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <refObject xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K-U</allAuthors>
            <date>2005</date>
            <issue>2</issue>
            <journalName>Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>381-90</pages>
            <title>Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride</title>
            <type>Journal article</type>
            <volume>30</volume>
        </refObject>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kuhn KU</allAuthors>
            <date>2006</date>
            <issue>6</issue>
            <journalName>Biological Psychiatry</journalName>
            <originalTitle></originalTitle>
            <pages>536-45</pages>
            <title>Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine</title>
            <type>Journal article</type>
            <volume>59</volume>
        </referenceList>
        <referenceList xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="journalReferenceObject">
            <allAuthors>Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K-U</allAuthors>
            <date>2005</date>
            <issue>2</issue>
            <journalName>Neuropsychopharmacology</journalName>
            <originalTitle></originalTitle>
            <pages>381-90</pages>
            <title>Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride</title>
            <type>Journal article</type>
            <volume>30</volume>
        </referenceList>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kuhn KU</references>
        <references>Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine</references>
        <references>Biological Psychiatry</references>
        <references>2006</references>
        <references>59</references>
        <references>6</references>
        <references>536-45</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>United States</references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K-U</references>
        <references>Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride</references>
        <references>Neuropsychopharmacology</references>
        <references>2005</references>
        <references>30</references>
        <references>2</references>
        <references>381-90</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>United States</references>
        <references></references>
        <reportingBiasJudgement>Additional treatment with biperiden up to 4mg/day was permitted, but data on use of antiparkinson medication was not available.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Wagner-2005</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>No further details.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Random, medication containers according to a pseudo-random computer algorithm.</selectionBiasRandomSequenceJudgement>
        <setting>INPATIENT</setting>
        <trialDesign>PARALLEL</trialDesign>
        <year>2005</year>
    </TRIAL>
</database>
